12:11 PM EST - Cardiome Pharma Corp. : said that its phase 3 European Comparator Study evaluating vernakalant (iv) versus amiodarone for the acute conversion of atrial fibrillation met its primary endpoint. The late-stage trial, called the AVRO study, achieved statistical significance in demonstrating the superiority of vernakalant (iv) over amiodarone in the conversion of atrial fibrillation to sinus rhythm within 90 minutes of the start of drug administration. Overall the data suggests that vernakalant (iv) was well tolerated in the study population. There were no vernakalant-related deaths or cases of "Torsades de Pointes", a specific and well-characterized ventricular arrhythmia. Cardiome Pharma Corp.
shares T.COM are trading up $0.10 at $4.35.
